To appraise the clinical and cost effectiveness of encorafenib in combination with binimetinib within its marketing authorisation for treating advanced unresectable or metastatic BRAF V600 mutation-positive melanoma.
Status Proposed
Process STA
ID number 923

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
22 September 2017 - 20 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance